Sun et al. recently reported a panel of stool-based DNA biomarkers for CRC screening in a format similar to Cologuard test, including the same two methylation biomarkers in our study, mSFRP2 and mSDC2, seven mutation sites of KRAS gene and one immunochemical assay for human hemoglobin, which showed sensitivities of 91.4% and 60% respectively for CRC and AA with a specificity of 86.1% 26. Here, KRAS is linked to colorectal carcinoma.